Australian Clinical Labs Ltd
ASX:ACL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (3.7), the stock would be worth AU$3.15 (56% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.3 | AU$2.02 |
0%
|
| 3-Year Average | 3.7 | AU$3.15 |
+56%
|
| 5-Year Average | 3.7 | AU$3.19 |
+58%
|
| Industry Average | 13.8 | AU$11.88 |
+488%
|
| Country Average | 13.2 | AU$11.37 |
+463%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Australian Clinical Labs Ltd
ASX:ACL
|
386.3m AUD | 2.3 | 14.7 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
97.1B USD | 9.1 | 54.9 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.3B EUR | 8.2 | 13.2 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.4B USD | 0 | 12.1 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.9B EUR | 9 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23B EUR | 8.6 | 23.6 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.4B USD | 11.9 | 22.7 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.4B USD | 13.6 | 25.5 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.9B EUR | 4.1 | 11.3 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.7B USD | -63.3 | -28.1 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 5.5 | 14 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.9 |
| Median | 13.2 |
| 70th Percentile | 19.2 |
| Max | 8 864.3 |
Other Multiples
Australian Clinical Labs Ltd
Glance View
Australian Clinical Labs Ltd. provides pathology services. The company is headquartered in Melbourne, Victoria and currently employs 2,794 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in private hospital pathology businesses in regions of Western Australia, Victoria, South Australia and the Northern Territory. Its brands include Australian Clinical Labs, SunDoctors, Helix Pathology, Southern Sun, BeFunctional Labs and Gribbles Veterinary Pathology. The Australian Clinical Labs provides pathology in Australia, servicing clinicians, patients, hospitals, commercial clients and public organizations. The SunDoctors offers diagnosis and treatment of skin cancer. The Helix Pathology delivers specialized histopathology and cytology testing services. The Southern Sun is the skin cancer lab and the commercial lab in Australia. The BeFunctional Labs assists practitioners in the diagnosis, treatment and management of patients by providing functional pathology tests. The Gribbles Veterinary Pathology provides animal health professionals with pathology service.
